Sphingosine-1-Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Narrative Review Focusing on Safety
Ozanimod and etrasimod, two new drugs for ulcerative colitis, work by stopping lymphocytes from reaching the inflamed colon, leading to reduced inflammation and improved symptoms. While clinical trials indicate a manageable safety profile, potential for cardiovascular, ocular, hepatic, pulmonary, and infectious complications necessitates precautions and careful monitoring.